LSPedia Secures Major Investment to Advance AI in Pharma Supply Chains

FARMINGTON HILLS, MI – May 26, 2026 – LSPedia, a key provider of pharmaceutical supply chain software, has secured a major strategic growth investment from private equity firm Bregal Sagemount. The infusion of capital, provided through Sagemount's Basecamp fund, is set to accelerate the company's mission to move beyond regulatory compliance and build a more intelligent, predictive, and secure global pharmaceutical supply chain.

The partnership validates LSPedia's significant role in a market shaped by stringent government regulations and the ever-present threat of counterfeit drugs. For an industry where the integrity of the supply chain is directly linked to patient safety, the investment signals a pivotal shift towards leveraging advanced technology not just to meet rules, but to create new operational efficiencies.

The Regulatory Imperative Driving Growth

The demand for solutions like those offered by LSPedia is not speculative; it is mandated by law. The U.S. Drug Supply Chain Security Act (DSCSA), enacted in 2013, has been the primary catalyst. The final phase of this regulation, which requires an electronic, interoperable system for tracing prescription drugs at the individual package level, is set for enforcement on November 27, 2024. After a one-year "stabilization period" granted by the FDA to prevent supply chain disruptions, the industry is now facing a hard deadline to comply.

This regulatory pressure has ignited a multi-billion dollar market. Industry analyses project the global pharma track and trace solutions market, valued at approximately $2.8 billion in 2025, to surge to nearly $7 billion by 2033. This growth is driven by the need for pharmaceutical manufacturers, wholesale distributors, and dispensers to invest heavily in systems that can manage the immense volume of serialization data required for compliance. Similar regulations, like the Falsified Medicines Directive (FMD) in Europe, further amplify the need for a global solution, which LSPedia supports across 40 countries.

"LSPedia has built a uniquely comprehensive platform that serves participants across the entire pharmaceutical supply chain," said Zuhair Khan, Partner and Co-Head of Basecamp at Sagemount. "The Company’s focus on helping customers meet regulatory requirements while also providing operational value creates a compelling foundation for long-term growth."

From Bootstrapped Vision to Strategic Partnership

LSPedia's journey to securing this investment is a story of focused, founder-led growth. Founded in 2013 by Riya Cao, the company was bootstrapped from the ground up, built with a deep understanding of the pharmaceutical industry's operational realities. This approach allowed the company to develop its platform without outside influence, focusing squarely on solving the complex challenges of serialization and traceability.

Over the past decade, this strategy has paid off. LSPedia now serves over 1,600 customers, including major healthcare brands like Cencora, Cardinal Health, and the U.S. Department of Veterans Affairs. Its network processes over 900 million serialized units annually across more than 750,000 trading partner connections, making it one of the largest data processors in the industry.

This profile of a profitable, founder-owned, and market-leading company made LSPedia an ideal candidate for Bregal Sagemount’s Basecamp fund. The fund specifically targets such businesses for investments between $20 million and $75 million, aiming to help them scale without losing their entrepreneurial core. The partnership is therefore not just a financial transaction but a strategic alignment of visions.

"We built LSPedia from the ground up, bootstrapped with a focus on the operational realities of pharmaceutical compliance," said Riya Cao, Founder and CEO of LSPedia. "Together with Sagemount, we see a significant opportunity to continue expanding the platform, deepening customer relationships, and investing in the next generation of supply chain connectivity and intelligence."

Beyond Compliance: The Future is Predictive and Automated

While DSCSA compliance is the immediate driver for many customers, LSPedia's vision—and the focus of this new investment—extends far beyond checking regulatory boxes. The company is positioning itself at the forefront of supply chain innovation with its OneScan platform and advanced Traceability AI.

The flagship OneScan solution is designed to simplify the immense complexity of serialization. Its "scan-once" workflow enables warehouse staff to capture product data at any point—receiving, packing, or shipping—and have the system automatically route the right information to the right trading partner or internal system. This drastically reduces the operational friction and potential for human error that can cripple supply chain speed. The platform also includes the Investigator module, a critical tool for managing the inevitable data exceptions and errors that occur in EPCIS data exchanges, allowing trading partners to resolve issues collaboratively and in real time.

The true game-changer, however, lies in the application of artificial intelligence. With the new funding, LSPedia plans to aggressively expand its Traceability AI capabilities. A prime example is its Serialized Recall Management Module, which automates one of the most critical and time-sensitive processes in the industry. Instead of relying on manual communication and siloed data, the AI-powered module continuously monitors for recall signals, initiates automated workflows, and can pinpoint affected products down to the serial number across the entire supply chain. LSPedia projects this can reduce recall response times by up to 90%, a life-saving improvement.

"With innovations like OneScan and Traceability AI, we’re helping customers achieve supply chain visibility, integration, and predictive insights with the speed and scale today’s environment demands," Cao added. This transformation of compliance data into actionable, predictive intelligence is what sets the company apart in a crowded market.

A Competitive Edge in a Crowded Market

LSPedia operates in a competitive field with established players like rfxcel and TraceLink. However, its strategic focus on pairing operational efficiency with compliance provides a distinct advantage. While competitors also offer track-and-trace solutions, LSPedia's emphasis on a unified platform that solves real-world warehouse problems while simultaneously ensuring regulatory adherence has resonated with the market.

The scale of its network gives it a powerful data advantage, which is the fuel for its advanced AI ambitions. By processing nearly a billion serialized transactions a year, the company gains unparalleled insight into supply chain dynamics, which can be used to refine its predictive models and deliver greater value to customers. The investment from Bregal Sagemount provides the resources to not only enhance these technological capabilities but also to expand its global footprint and customer support infrastructure.

This partnership equips LSPedia to accelerate its roadmap, focusing on deeper integrations and more sophisticated analytics. For a pharmaceutical industry grappling with complex global supply chains, looming regulatory deadlines, and the constant need to ensure patient safety, the move toward an intelligent, AI-driven traceability platform represents the clear path forward. The collaboration between LSPedia's domain expertise and Sagemount's growth capital is poised to play a significant role in shaping that future.